NO321061B1 - Anvendelse av moksonidin til fremstilling av legemidler for behandling etter hjerteinfarkt - Google Patents
Anvendelse av moksonidin til fremstilling av legemidler for behandling etter hjerteinfarkt Download PDFInfo
- Publication number
- NO321061B1 NO321061B1 NO20013753A NO20013753A NO321061B1 NO 321061 B1 NO321061 B1 NO 321061B1 NO 20013753 A NO20013753 A NO 20013753A NO 20013753 A NO20013753 A NO 20013753A NO 321061 B1 NO321061 B1 NO 321061B1
- Authority
- NO
- Norway
- Prior art keywords
- myocardial infarction
- moxonidine
- treatment
- rats
- heart
- Prior art date
Links
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 59
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 229960003938 moxonidine Drugs 0.000 title abstract description 41
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 15
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 11
- 206010000891 acute myocardial infarction Diseases 0.000 claims abstract description 4
- 210000004165 myocardium Anatomy 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 abstract description 17
- 230000007574 infarction Effects 0.000 abstract description 13
- 230000002107 myocardial effect Effects 0.000 abstract description 9
- 206010019280 Heart failures Diseases 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 230000003680 myocardial damage Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 46
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000008700 sympathetic activation Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000002820 sympathetic nervous system Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000003943 catecholamines Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000006029 Cardiomegaly Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- -1 aliphatic mono- Chemical class 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BVZUBMFQVJEKKD-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)pyrimidin-5-amine Chemical class N1CCN=C1NC1=CN=CN=C1 BVZUBMFQVJEKKD-UHFFFAOYSA-N 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000004346 regulation of heart rate Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Details Of Spanners, Wrenches, And Screw Drivers And Accessories (AREA)
- Heat Treatment Of Articles (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fire-Extinguishing Compositions (AREA)
- Farming Of Fish And Shellfish (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19903780 | 1999-02-01 | ||
| PCT/EP2000/000655 WO2000045820A1 (de) | 1999-02-01 | 2000-01-28 | Verwendung von moxonidin zur behandlung nach herzinfarkt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013753D0 NO20013753D0 (no) | 2001-07-31 |
| NO20013753L NO20013753L (no) | 2001-09-28 |
| NO321061B1 true NO321061B1 (no) | 2006-03-06 |
Family
ID=7895940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013753A NO321061B1 (no) | 1999-02-01 | 2001-07-31 | Anvendelse av moksonidin til fremstilling av legemidler for behandling etter hjerteinfarkt |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7041303B2 (pl) |
| EP (1) | EP1150680B1 (pl) |
| JP (1) | JP4686027B2 (pl) |
| KR (1) | KR20010092793A (pl) |
| CN (1) | CN1166363C (pl) |
| AT (1) | ATE286731T1 (pl) |
| AU (1) | AU774855B2 (pl) |
| BR (1) | BR0007894A (pl) |
| CA (1) | CA2361600C (pl) |
| CZ (1) | CZ20012615A3 (pl) |
| DE (2) | DE10003771A1 (pl) |
| DK (1) | DK1150680T3 (pl) |
| ES (1) | ES2235829T3 (pl) |
| HK (1) | HK1042650B (pl) |
| HU (1) | HUP0105210A3 (pl) |
| IL (1) | IL144621A (pl) |
| NO (1) | NO321061B1 (pl) |
| NZ (1) | NZ513869A (pl) |
| PL (1) | PL195124B1 (pl) |
| PT (1) | PT1150680E (pl) |
| RU (1) | RU2261097C2 (pl) |
| SK (1) | SK10082001A3 (pl) |
| TR (1) | TR200102221T2 (pl) |
| UA (1) | UA67822C2 (pl) |
| WO (1) | WO2000045820A1 (pl) |
| ZA (1) | ZA200105827B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102850331B (zh) * | 2012-09-17 | 2015-05-20 | 符爱清 | 一种化合物的制备方法 |
| CN103483268B (zh) * | 2013-09-17 | 2015-10-14 | 常州大学 | 一种4,6-二氯-2-甲基-5-硝基嘧啶的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3739779A1 (de) * | 1987-11-24 | 1989-06-08 | Beiersdorf Ag | Pharmazeutische praeparate |
| AU3233197A (en) * | 1996-06-06 | 1998-01-05 | Eli Lilly And Company | Formulation and method for treating congestive heart failure |
-
2000
- 2000-01-28 NZ NZ513869A patent/NZ513869A/xx unknown
- 2000-01-28 JP JP2000596940A patent/JP4686027B2/ja not_active Expired - Fee Related
- 2000-01-28 CZ CZ20012615A patent/CZ20012615A3/cs unknown
- 2000-01-28 SK SK1008-2001A patent/SK10082001A3/sk unknown
- 2000-01-28 CN CNB008032440A patent/CN1166363C/zh not_active Expired - Fee Related
- 2000-01-28 IL IL14462100A patent/IL144621A/en not_active IP Right Cessation
- 2000-01-28 PT PT00902638T patent/PT1150680E/pt unknown
- 2000-01-28 TR TR2001/02221T patent/TR200102221T2/xx unknown
- 2000-01-28 AT AT00902638T patent/ATE286731T1/de not_active IP Right Cessation
- 2000-01-28 DK DK00902638T patent/DK1150680T3/da active
- 2000-01-28 UA UA2001075408A patent/UA67822C2/uk unknown
- 2000-01-28 BR BR0007894-8A patent/BR0007894A/pt not_active IP Right Cessation
- 2000-01-28 EP EP00902638A patent/EP1150680B1/de not_active Expired - Lifetime
- 2000-01-28 KR KR1020017009232A patent/KR20010092793A/ko not_active Application Discontinuation
- 2000-01-28 DE DE10003771A patent/DE10003771A1/de not_active Withdrawn
- 2000-01-28 HU HU0105210A patent/HUP0105210A3/hu unknown
- 2000-01-28 CA CA002361600A patent/CA2361600C/en not_active Expired - Fee Related
- 2000-01-28 ES ES00902638T patent/ES2235829T3/es not_active Expired - Lifetime
- 2000-01-28 AU AU24404/00A patent/AU774855B2/en not_active Ceased
- 2000-01-28 DE DE50009220T patent/DE50009220D1/de not_active Expired - Lifetime
- 2000-01-28 RU RU2001121019/14A patent/RU2261097C2/ru not_active IP Right Cessation
- 2000-01-28 PL PL00350559A patent/PL195124B1/pl not_active IP Right Cessation
- 2000-01-28 WO PCT/EP2000/000655 patent/WO2000045820A1/de not_active Application Discontinuation
-
2001
- 2001-07-16 ZA ZA200105827A patent/ZA200105827B/en unknown
- 2001-07-31 NO NO20013753A patent/NO321061B1/no unknown
- 2001-07-31 US US09/917,858 patent/US7041303B2/en not_active Expired - Fee Related
-
2002
- 2002-05-31 HK HK02104090.9A patent/HK1042650B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI508726B (zh) | 治療心房纖維性顫動之方法 | |
| JP5968927B2 (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
| JPH02121922A (ja) | Ａｃｅ阻害剤の使用 | |
| NO321061B1 (no) | Anvendelse av moksonidin til fremstilling av legemidler for behandling etter hjerteinfarkt | |
| JP2015512919A (ja) | 塩酸レルカニジピンおよびロサルタンカリウム配合剤およびその調製法 | |
| CN101474195B (zh) | 一种治疗心脑血管疾病的药物组合物 | |
| JP3993647B2 (ja) | β−ナフトキノン誘導体及びそれらの塩類の新規な用途 | |
| CN103861081B (zh) | 一种培哚普利氨氯地平片剂及其生产工艺 | |
| CA2754839C (en) | Pharmaceutical composition comprising levamlodipine and chlorthalidone | |
| EP1863492B1 (en) | Use of megestrol acetate for improving heart function and the treatment of heart insufficiency | |
| CN109820855A (zh) | 常山酮在制备用于治疗和预防缺血性心脏病药物中的应用 | |
| MXPA01007614A (en) | Use of moxonidine for postmyocardial infarction treatment | |
| US4218466A (en) | Method of treating gastric and duodenal ulcers | |
| CN101632666B (zh) | 用于治疗高血压的药物组合物 | |
| CN109364043A (zh) | 一种治疗甲状腺功能异常的缓控释药物组合物 | |
| RU2392939C1 (ru) | Способ профилактики нарушений ритма сердца при коронарном шунтировании | |
| CN110876799A (zh) | 米卡芬净在制备治疗缺血/再灌注损伤药物中的应用 | |
| RU2314099C1 (ru) | Фармацевтическая композиция | |
| CN103040817A (zh) | 一种用于治疗高血压的复方制剂 | |
| KR20100011465A (ko) | 커큐민을 유효성분으로 포함하는 피판 치료용 조성물 |